On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 03/02/21
- Point72 Asset Management reports 5.5% passive stake in Paya Holdings
- 02/25/21
- Paya's FIrst Billings Services, Agent 511 announce strategic partnership
- 02/09/21
- Paya Holdings' payment solution certified by Acumatica
- 11/02/20
- Paya Holdings appoints Matt Humphries as head of investor relations
- 03/15/21
- Facebook, News Corp reach multi-year agreement in Australia
- 03/15/21
- News Corp jumps 3.5% to $25.58 after disclosing Rupert Murdoch insider buy
- 03/15/21
- News Corp executive chairman buys 500K shares of common stock
- 02/17/21
- News Corp, Google agree to three-year news partnership
- 02/25/21
- Nikola sees delivering first Nikola Tre BEVs to customers during Q4
- 02/25/21
- Nikola CEO says 'necessary changes' made in Q4 to 'refocus and realign' company
- 02/23/21
- Nikola provides update on North American hydrogen fuel-cell vehicle program
- 01/14/21
- Worthington sells it remaining 7.05M shares of Nikola
- 03/10/21
- Maxar Technologies completes Spider robotic arm Critical Design Review for NASA
- 01/21/21
- Maxar Technologies falls -7.3%
- 01/14/21
- Maxar Technologies rises 27.9%
- 01/14/21
- Maxar Technologies rises 14.3%
- 03/15/21
- Inspire Medical gets FDA approval of two-incision implant procedure
- 01/19/21
- Inspire appoints Bryan Phillips as chief compliance officer, general counsel
- 11/03/20
- Inspire Medical rises 23.2%
- 11/03/20
- Inspire Medical rises 19.1%
- 03/11/21
- Imax and visual effect company Maximus in JV, for in-home A.I. video enhancement
- 03/10/21
- Imax, Broadway sign new four-theatre deal in Shanghai
- 03/09/21
- Imax signs 4-theater deal in Shanghai with exhibitor Broadway
- 03/05/21
- Imax rises 9.4%
- 03/08/21
- HealthEquity acquires Luum, terms not disclosed
- 01/11/21
- HealthEquity expects 5.7M-5.8M HSA members by Jan. 31
- 03/09/21
- CleanSpark acquires 1,150 new miners capable of producing 100 PH/s
- 02/09/21
- CleanSpark provides acquisition update on Bitcoin mining operations
- 02/03/21
- CleanSpark announces multi-unit switchgear order for commercial microgrids
- 01/21/21
- CleanSpark says investigating short seller Culper Research, calls claims 'false'
- $11.15 /
+1.155 (+11.56%) - 01/05/21
- AerSale announces additional Boeing 757 conversions at Arizona facility
- 12/29/20
- Amphastar jumps 26% to $23.98 after FDA approval for generic glucagon kit
- 12/29/20
- Amphastar announces approval for Glucagon for Injection Kit, 1mg
- 12/28/20
- Amphastar granted FDA approval of generic glucagon for injection
- 10/06/20
- Amphastar receives FDA approval for Atropine Sulfate injection
- 03/15/21
- AcelRx sees FY21 CapEx $4M-$5M
- 02/17/21
- AcelRx signs agreement for study of Dsuvia in plastic surgery
- 02/16/21
- FDA posts warning letter sent to AcelRx over Dsuvia marketing materials
- 01/19/21
- AcelRx announces investigator-initiated study to evaluate DSUVIA
- 02/11/21
- Fly Intel: Top five analyst initiations
- 02/11/21 Maxim
- Zedge initiated with a Buy at Maxim
- 01/08/21 Wells Fargo
- Amphastar downgraded to Equal Weight from Overweight at Wells Fargo
- 10/05/20 Northland
- Amphastar upgraded to Outperform from Market Perform at Northland
- 07/09/20 Northland
- Amphastar downgraded to Market Perform from Outperform at Northland
- 05/01/20
- Fly Intel: Top five analyst initiations
- 02/24/21 Lake Street
- Inspire Medical price target raised to $250 from $215 at Lake Street
- 02/24/21 SVB Leerink
- Inspire Medical price target raised to $275 from $225 at SVB Leerink
- 02/24/21 Piper Sandler
- Inspire Medical price target raised to $252 from $210 at Piper Sandler
- 01/07/21 Lake Street
- Inspire Medical price target raised to $215 from $150 at Lake Street
- 02/17/21 H.C. Wainwright
- AcelRx warning letter is a 'nothingburger,' says H.C. Wainwright
- 07/24/20 H.C. Wainwright
- AcelRx deal with Zimmer Biomet a 'win-win,' says H.C. Wainwright
- 07/20/20
- Fly Intel: Top five analyst downgrades
- 07/20/20 Credit Suisse
- AcelRx downgraded to Underperform on 'mounting challenges' at Credit Suisse
- $11.15 /
+1.155 (+11.56%) - 01/07/21 Cowen
- AerSale initiated with a Market Perform at Cowen
- 02/10/21 Raymond James
- HealthEquity price target raised to $100 from $75 at Raymond James
- 02/09/21 Barrington
- HealthEquity price target raised to $90 from $75 at Barrington
- 02/09/21 Truist
- HealthEquity price target raised to $92 from $80 at Truist
- 02/09/21 RBC Capital
- HealthEquity price target raised to $87 from $74 at RBC Capital
- 03/10/21 BTIG
- CleanSpark initiated with a Buy at BTIG
- 03/10/21 BTIG
- CleanSpark initiated with a Buy at BTIG
- 02/16/21 H.C. Wainwright
- CleanSpark price target raised to $50 from $24 at H.C. Wainwright
- 12/11/20 H.C. Wainwright
- CleanSpark price target raised to $24 from $18 at H.C. Wainwright
- 03/09/21 Barrington
- Imax price target raised to $27 from $25 at Barrington
- 03/05/21 Macquarie
- Imax price target raised to $25 after Q4 earnings beat at Macquarie
- 03/05/21 Benchmark
- Imax price target raised to $24 from $22 at Benchmark
- 03/01/21 Wedbush
- Imax price target raised to $22 from $14 at Wedbush
- 03/05/21
- Fly Intel: Top five analyst downgrades
- 03/05/21 JPMorgan
- JPMorgan lowers Bloom Energy target but now prefers over Nikola
- 03/05/21 JPMorgan
- Nikola downgraded to Neutral from Overweight at JPMorgan
- 02/01/21
- Fly Intel: Top five analyst upgrades
- 06/26/20 B. Riley
- Rubicon Project meetings suggest Q2 outlook conservative, says B. Riley FBR
- 04/02/20 Craig-Hallum
- Rubicon Project price target lowered to $9 from $14 at Craig-Hallum
- 02/25/21 Canaccord
- Maxar Technologies price target raised to $55 from $50 at Canaccord
- 02/19/21 Canaccord
- Maxar Technologies price target raised to $50 from $40 at Canaccord
- 01/21/21
- Fly Intel: Top five analyst downgrades
- 01/21/21 JPMorgan
- JPMorgan downgrades Maxar, says take profits after 85% rally
- 03/08/21 BTIG
- Paya Holdings Q4 shows bull thesis intact, says BTIG
- 02/26/21 Raymond James
- Paya Holdings initiated with an Outperform at Raymond James
- 02/23/21 DA Davidson
- Paya Holdings initiated with a Buy at DA Davidson
- 02/23/21 DA Davidson
- Paya Holdings initiated with a Buy at DA Davidson
- 03/15/21
- Zedge reports Q2 EPS 17c, one estimate 4c
- 03/08/21
- Paya Holdings sees FY21 revenue $234M-$242M, consensus $237.97M
- 03/08/21
- Paya Holdings reports Q4 revenue $54M consensus $53.3M
- 11/09/20
- Paya Holdings reports Q3 revenue $51.8M, consensus $53.35M
- 02/04/21
- News Corp. reports Q2 adjutsed EPS 34c, consensus 10c
- 11/05/20
- News Corp. reports Q1 adjusted EPS 8c, consensus 0c
- 02/25/21
- Nikola reports Q4 adjusted EPS (17c), consensus (23c)
- 02/25/21
- Notable companies reporting after market close
- 11/09/20
- Nikola reports Q3 adjusted EPS (16c), consensus (19c)
- 11/09/20
- Notable companies reporting after market close
- 02/24/21
- Maxar Technologies reports Q4 EPS (65c) vs 70c last year
- 11/05/20
- Maxar Technologies maintains FY20 adj. EBITDA view of $415M-$445M
- 11/02/20
- Inspire Medical raises FY20 revenue view to $110M-$112M from $88M-$92M
- 11/02/20
- Inspire Medical reports Q3 EPS (39c), consensus (72c)
- 03/04/21
- Imax reports Q4 adjusted EPS (21c), consensus (20c)
- 10/29/20
- Imax reports Q3 EPS (75c), consensus (30c)
- 03/15/21
- HealthEquity sees FY22 EPS $1.37-$1.42, consensus $1.70
- 03/15/21
- HealthEquity reports Q4 EPS 42c, consensus 39c
- 03/15/21
- Notable companies reporting after market close
- 02/09/21
- HealthEquity raises FY21 EPS view to $1.67-$1.71 from $1.55-$1.61
- 10/21/20
- CleanSpark backs FY21 revenue view $20M, consensus $22.87M
- 10/21/20
- CleanSpark sees FY20 revenue over $10.0M, one estimate $10.22M
- $11.15 /
+1.155 (+11.56%) - 03/15/21
- AerSale reports Q4 adjusted EBITDA $3.3M vs. $23.8M last year
- 03/15/21
- Amphastar reports Q4 EPS 16c, consensus 14c
- 11/06/20
- Amphastar reports Q3 adjusted EPS 15c, consensus 14c
- 03/15/21
- AcelRx reports Q4 EPS (10c), consensus (10c)
- 01/14/21
- AcelRx reports preliminary FY20 revenue approximately $5.4M, consensus $7.25M
- 11/05/20
- AcelRx reports Q3 EPS (10c), consensus (8c)
|
Hot Stocks
|
Inspire Medical Systems… Inspire Medical Systems announced receipt of U.S. Food and Drug Administration approval for an improved surgical implant procedure that eliminates one incision with a revised placement of the pressure sensing lead. This newly approved procedure will reduce the average procedure time for Inspire therapy by approximately 20% ."Delivering consistent positive patient outcomes remains Inspire's number one priority, and the receipt of FDA approval for this two-incision procedure represents further evidence of our commitment to the continuous improvement of Inspire therapy," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "The new procedure places the sensor in the intercostal muscles directly behind the neurostimulator pocket, thereby eliminating the need for a third incision lower on the chest and the additional requirement to tunnel the sensing lead under the skin to the neurostimulator. A number of ENT surgeons highly experienced with the current Inspire implant procedure initiated the development of this new surgical technique. With this approval, we now intend to leverage our broad network of leading ENT's to further improve the Inspire procedure and enhance therapy outcomes." ShowHide Related Items >><< - 01/19/21
- Inspire appoints Bryan Phillips as chief compliance officer, general counsel
- 11/03/20
- Inspire Medical rises 23.2%
- 11/03/20
- Inspire Medical rises 19.1%
- 10/22/20
- Inspire Medical appoints Shelley Broader to board of directors
- 02/24/21 Lake Street
- Inspire Medical price target raised to $250 from $215 at Lake Street
- 02/24/21 SVB Leerink
- Inspire Medical price target raised to $275 from $225 at SVB Leerink
- 02/24/21 Piper Sandler
- Inspire Medical price target raised to $252 from $210 at Piper Sandler
- 01/07/21 Lake Street
- Inspire Medical price target raised to $215 from $150 at Lake Street
- 11/02/20
- Inspire Medical raises FY20 revenue view to $110M-$112M from $88M-$92M
- 11/02/20
- Inspire Medical reports Q3 EPS (39c), consensus (72c)
|